

STIC-ILL

5533/5

From: Davis, Minh-Tam
Sent: Wednesday, August 31, 2005 11:48 AM
To: STIC-ILL
Subject: REPRINT REQUEST FOR 10/069973

NO. _____ Address _____
NO. _____ Office _____ MAIL _____
NO. _____ NO. _____
NO. _____ NO. _____
NO. _____ NO. _____

8/31

EC

Mitochondrial permeability transition in CNS trauma: Cause or effect of neuronal cell death?

AUTHOR: Sullivan P G (Reprint); Rabchevsky A G; Waldmeier P C; Springer J E
AUTHOR ADDRESS: Spinal Cord and Brain Injury Res Ctr, Univ Kentucky, 240
HSRB, Lexington, KY, 40536, USA**USA
AUTHOR E-MAIL

2) Long-term follow-up and complications after cardiac transplantation.

Conrad S A; Chhabra A; Vay D
Willis Knighton-LSU Medical Center Heart and Lung Transplantation Center
in Shreveport.
Journal of the Louisiana State Medical Society - official organ of the
Louisiana State Medical Society (UNITED STATES) May 1993 , 145 (5)
p217-20, 223-5, ISSN 0024-6921 Journal Code: 7505618
Publishing Model Print

8340685

3) Prevention of cardiac hypertrophy in mice by calcineurin inhibition.

Sussman M A; Lim H W; Gude N; Taigen T; Olson E N; Robbins J; Colbert M C
; Gualberto A; Wieczorek D F; Molkentin J D
Division of Molecular Cardiovascular Biology, Children's Hospital Medical
Center, 3333 Burnet Avenue, Cincinnati, OH 45229, USA.
Science (UNITED STATES) Sep 11 1998 , 281 (5383) p1690-3,
0036-8075 Journal Code: 0404511

COMPLETED

8/3

THANK YOU
MINH TAM DAVIS
ART UNIT 1642, ROOM 3A24, MB 3C18
272-0830

17949438

BEST AVAILABLE COPY

LONG-TERM FOLLOW-UP AND COMPLICATIONS AFTER CARDIAC TRANSPLANTATION

STEVEN A. CONRAD, MD, PHD; ANIL CHHABRA, MD;
DEBBIE VAY, RN, CCRN

Cardiac transplantation has become an established therapy for cardiomyopathy and other irreversible cardiac diseases. Improvements in immunosuppression and management of infections has improved long-term survival following transplantation. The role of the primary care physician in the care of recipients will be expanding.

Transplant recipients receive close outpatient follow-up after discharge, primarily to monitor immunosuppression through laboratory evaluation and drug levels, monitor for rejection through endomyocardial biopsy, and to assess for any signs of opportunistic infection. The foundation for long-term immunosuppression is administration of cyclosporin, azathioprine and corticosteroids. Antibiotic prophylaxis is used to decrease the chance of infection with cytomegalovirus, *Pneumocystis*, *Candida*, *Toxoplasma*, and other opportunistic organisms. The major long-term complications include rejection, infection, hypertension, renal dysfunction, lipid abnormalities, and accelerated coronary atherosclerosis.

This review provides an overview of the short- and long-term follow-up of the cardiac transplant recipient, including routine care as well as detection and management of the common complications.

SINCE THE first cardiac transplant 26 years ago in South Africa by Dr Christian Barnard, newer immunosuppressive agents have changed the long-term outcome and success in all transplant patients. In 1991 approximately 2949 cardiac transplants were performed worldwide and of these, 2125 were performed in the United States. With improved immunosuppression, this population will continue to grow and require close participation of primary care physicians away from the transplant center.

In spite of the improvement in survival, however, there are no universally accepted standards for patient follow-up and management in the postoperative period. Each transplant center has adopted its own patient care and immunosuppression protocols, usually derived by modification of protocol from other centers. Although each center is different, there is a great deal of similarity among centers in long-term management of recipients.

The purpose of this article is to review the general aspects of outpatient follow-up and management of the cardiac transplant recipient, once the patient has left the hospital following the initial transplant procedure. It should provide insight into those aspects of care that can be managed outside a transplantation center, and indicate when to refer patients back to the center for definitive care.

OUTPATIENT FOLLOW-UP

General Aspects. After discharge from the hospital following the transplantation procedure, the patient remains in the transplant center community for several weeks. In the immediate postdischarge period, patients are followed twice weekly for 6 weeks in the Heart Transplant Clinic by the transplant coordinator and physician. During this period the patient is monitored for any evidence of rejection or infection, and ►

TABLE 1 OUTPATIENT CLINIC SCHEDULE FOR HEART TRANSPLANT RECIPIENTS	
Period	Frequency
Weeks 1 through 6	Twice weekly
Months 2 through 4	Monthly
Months 6 and later	Every 3 months

drug levels of immunosuppressive agents are followed. An important aspect of the immediate postdischarge period is the continuation of the patient and family education that was initiated preoperatively during the waiting period. After the initial 6 weeks, patients are followed at preset intervals unless their condition warrants closer monitoring. Before release to the home community, the patients are seen at longer intervals, depending on the patient's biopsy schedule. Table 1 summarizes the Willis Knighton-LSU Medical Center Heart Transplant Clinic outpatient schedule.

Clinic visits routinely consist of physical examination, laboratory studies, drug levels, ECG, chest radiography, echocardiography, and review of endomyocardial biopsies.

Physical Examination. A complete physical examination is performed at each clinic visit, aimed at detecting evidence of infection, cardiovascular dysfunction, renal dysfunction, hypertension, problems with fluid balance, and adverse effects of medication. An accurate weight is recorded at each visit. Vital signs are obtained in supine, sitting, and standing positions. The oropharyngeal cavity is examined for evidence of infection or colonization. Special emphasis is placed on the cardiovascular examination, looking for neck vein distention, pulmonary or peripheral edema, and gallop. The lungs are auscultated for evidence of pulmonary parenchymal or airway disease. The abdomen is examined for hepatosplenomegaly and tenderness. The skin is carefully examined for lesions.

Laboratory Studies. A variety of laboratory tests are obtained on a scheduled basis following transplantation. A CBC with differential white count and platelet count are obtained at each visit. The white count is used to guide dosing of azathioprine. Excessive immunosuppression can be detected by following the hemoglobin and the platelet count. Opportunistic infections which affect the bone marrow may also be suspected

from the CBC. A chemistry profile is also obtained at each visit, especially to detect adverse renal or hepatic effects of drug (especially cyclosporin) therapy. Cyclosporin trough levels are measured at each visit and help to guide cyclosporin dosing, especially in the face of renal or hepatic insufficiency.

Serology for Epstein-Barr virus, cytomegalovirus and *Toxoplasma* are obtained weekly for 6 weeks, then monthly until the fourth postoperative month. Surveillance cultures of the throat and urine are obtained weekly for 6 weeks. Blood and urine are cultured for CMV weekly for 6 weeks, then monthly until 4 months. Hepatitis C serology is obtained at 3 months if the donor was HCV positive and the recipient negative.

Lipid profiles are obtained at 3 and 6 months, then subsequently every 6 months. Complete pulmonary function tests and 24-hour creatinine clearance are obtained at 6 months and 1 year, then yearly thereafter.

Electrocardiogram. The ECG was important for the diagnosis of rejection in the precyclosporin era. A drop in summated voltages of the limb leads, V1 and V6 of 20% or more was relatively sensitive for an acute rejection episode. However, the ECG is relatively insensitive in detecting rejection when cyclosporin is part of the immunosuppressant regimen.¹ In these patients, it is perhaps more helpful for identifying rhythm disturbances or detecting asymptomatic myocardial ischemia or infarction. The ECG still remains useful for assessing for rejection in patients who are unable to take cyclosporin, or who have been tapered off of the drug. An ECG is obtained at each clinic visit.

Chest Radiograph. Chest radiography is an important part of the follow-up of cardiac transplant recipients. The lung is the most commonly infected organ, and some pulmonary infections may have an insidious course. Because of this fact and the knowledge that the immunosuppression regimen can mask early signs of infection, the chest radiograph is an important means of identifying pulmonary infections early in the course. We obtain a chest radiograph at every clinic visit for comparison with previous studies and in patients who develop symptoms of upper respiratory or pulmonary infection, even if the physical examination does not yield any positive findings.

Echocardiography. One of the goals in transplantation medicine is to develop noninvasive methods of detecting rejection. Since rejection is associated with impairment of myocardial function, echocardiographic assessment holds some promise for detection

of rejection. Unfortunately, most of the parameters of cardiac function determined by 2-D echocardiography, in particular systolic function, remain within normal limits during episodes of rejection in patients receiving cyclosporin. Although small changes from control values may occur in a given individual during rejection, the value of 2-D echocardiography is limited. Newer approaches involving Doppler echocardiographic determinations, such as isovolumetric relaxation time and pressure half time, are more useful.^{2,3}

When present, echocardiographic signs of rejection have a high specificity. However, the degree of abnormality on echocardiography may not correlate with the severity of rejection as determined by endomyocardial biopsy. Response to treatment of rejection can be followed by echocardiography, and failure of the echocardiographic abnormalities to reverse following therapy is a poor prognostic sign. We obtain echocardiographic studies routinely after transplantation. Following discharge from the hospital, 2-D and Doppler echocardiography are performed weekly for 6 weeks. Right ventricular dimensions, left ventricular dimensions and posterior wall thickness, and diastolic properties of the left ventricle by Doppler (isovolumetric relaxation time and pressure half time) are recorded. Since detection of left ventricular dysfunction often occurs later in rejection than can be detected histologically, Doppler echocardiography can supplement but not replace endomyocardial biopsy for detection of early rejection. In particular, the development of diastolic indices of rejection may indicate clinically unsuspected rejection and should prompt for urgent biopsy.

Endomyocardial Biopsy. With widespread use of cyclosporin, the risk of rejection has decreased dramatically; however, there are no reliable clinical signs of rejection. Rejection in the cyclosporin era can only be diagnosed reliably in its early phases by right ventricular endomyocardial biopsy; therefore, these are performed at regular intervals.^{4,5,6}

The first biopsy is performed prior to discharge from the hospital, and subsequently once a week for 6 weeks on an outpatient basis. After the first 6 weeks, biopsies are obtained on each clinic visit. If an episode of rejection is identified and treated, follow-up biopsy is performed in 2 to 4 weeks to monitor response to treatment, then according to routine schedule. After the first year, biopsies are performed every 6 months.

YOCON[®]

YOHIMBINE-HCl

Background: Yohimbine is a 2,3,7,8-tetrahydro-5H-yohimbane-6-carboxylic acid hydrochloride. The chemical structure is shown below. Also in Yohimbine Sulfate (H) brand, Yohimbine is an imidazoline alkaloid with chemical structure as shown below. Yohimbine powder is odorless. Each compressed tablet contains 10 mg (15.4 mg of Yohimbine Hydrochloride).

Action: Yohimbine blocks norepinephrine B-adrenergic receptors. Its action on peripheral blood vessels resembles that of norepinephrine, though it is weaker and of shorter duration. Yohimbine is a peripheral autonomic nervous system effectant to increase parasympathetic (cholinergic) and decrease sympathetic (adrenergic) activity. It is to be noted that in male sexual performance, erection is linked to cholinergic activity and to alpha-2 adrenergic blockade which may theoretically result in increased penile inflow, decreased penile outflow or both.

Yohimbine exerts a stimulating action on the mind and may increase anxiety. Such actions have not been adequately studied or related to dosage, although they appear to require high doses of the drug. Yohimbine has a mild anti-diuretic action, probably via stimulation of hypothalamic centers and release of posterior pituitary hormone.

Reportedly, Yohimbine exerts no significant influence on cardiac stimulation and other effects mediated by B-adrenergic receptors. Its effect on blood pressure, if any, would be to lower it, however no adequate studies are available to evaluate this effect in terms of Yohimbine dosage.

Indications: Yocon[®] is indicated as a sympatholytic and mydriatic. It may have activity as an aphrodisiac.

Contraindications: Heart diseases, and patient's sensitive to any effect. In view of the limited and inadequate information at hand, no precise contraindications can be offered or additional contraindications.

Warnings: Generally, this drug is not proposed for use in females and patients must not be used during pregnancy. Neither is this drug proposed for use in pediatric patients or cardio-renal patients with past or present disease history. It should not be used in conjunction with monoamine oxidase inhibitors such as antidepressants, or in psychiatric patients in general.

Adverse Reactions: Yohimbine may exaggerate the effects and produces a complex pattern of responses in lower doses than required to produce peripheral adrenergic blockade. These include a nervousness, a general pleasured central excitation including acceleration of locomotion and heart rate, increased motor activity, irritability and tremor, sweating, nausea and vomiting are common after parenteral administration of the drug. Also dizziness, headache, skin flushing, reported in some cases.

Dosage and Administration: Recommended dosage reported in treatment of erectile impotence: 1.3-3 tablets (10-30 mg) 3 times a day to adult males taken orally. Occasional side effects reported with this dosage are nausea, dizziness or nervousness. In the event of side effects, dosage may be reduced to 2 tablets 3 times a day, followed by gradual increase and stabilized in 1-2 day. Reported therapy not more than 10 weeks.

How Supplied: Oral tablets of Yocon[®] 10 mg, 15 mg, 30 mg, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg, 1000 mg, 1050 mg, 1100 mg, 1150 mg, 1200 mg, 1250 mg, 1300 mg, 1350 mg, 1400 mg, 1450 mg, 1500 mg, 1550 mg, 1600 mg, 1650 mg, 1700 mg, 1750 mg, 1800 mg, 1850 mg, 1900 mg, 1950 mg, 2000 mg, 2050 mg, 2100 mg, 2150 mg, 2200 mg, 2250 mg, 2300 mg, 2350 mg, 2400 mg, 2450 mg, 2500 mg, 2550 mg, 2600 mg, 2650 mg, 2700 mg, 2750 mg, 2800 mg, 2850 mg, 2900 mg, 2950 mg, 3000 mg, 3050 mg, 3100 mg, 3150 mg, 3200 mg, 3250 mg, 3300 mg, 3350 mg, 3400 mg, 3450 mg, 3500 mg, 3550 mg, 3600 mg, 3650 mg, 3700 mg, 3750 mg, 3800 mg, 3850 mg, 3900 mg, 3950 mg, 4000 mg, 4050 mg, 4100 mg, 4150 mg, 4200 mg, 4250 mg, 4300 mg, 4350 mg, 4400 mg, 4450 mg, 4500 mg, 4550 mg, 4600 mg, 4650 mg, 4700 mg, 4750 mg, 4800 mg, 4850 mg, 4900 mg, 4950 mg, 5000 mg, 5050 mg, 5100 mg, 5150 mg, 5200 mg, 5250 mg, 5300 mg, 5350 mg, 5400 mg, 5450 mg, 5500 mg, 5550 mg, 5600 mg, 5650 mg, 5700 mg, 5750 mg, 5800 mg, 5850 mg, 5900 mg, 5950 mg, 6000 mg, 6050 mg, 6100 mg, 6150 mg, 6200 mg, 6250 mg, 6300 mg, 6350 mg, 6400 mg, 6450 mg, 6500 mg, 6550 mg, 6600 mg, 6650 mg, 6700 mg, 6750 mg, 6800 mg, 6850 mg, 6900 mg, 6950 mg, 7000 mg, 7050 mg, 7100 mg, 7150 mg, 7200 mg, 7250 mg, 7300 mg, 7350 mg, 7400 mg, 7450 mg, 7500 mg, 7550 mg, 7600 mg, 7650 mg, 7700 mg, 7750 mg, 7800 mg, 7850 mg, 7900 mg, 7950 mg, 8000 mg, 8050 mg, 8100 mg, 8150 mg, 8200 mg, 8250 mg, 8300 mg, 8350 mg, 8400 mg, 8450 mg, 8500 mg, 8550 mg, 8600 mg, 8650 mg, 8700 mg, 8750 mg, 8800 mg, 8850 mg, 8900 mg, 8950 mg, 9000 mg, 9050 mg, 9100 mg, 9150 mg, 9200 mg, 9250 mg, 9300 mg, 9350 mg, 9400 mg, 9450 mg, 9500 mg, 9550 mg, 9600 mg, 9650 mg, 9700 mg, 9750 mg, 9800 mg, 9850 mg, 9900 mg, 9950 mg, 10000 mg, 10050 mg, 10100 mg, 10150 mg, 10200 mg, 10250 mg, 10300 mg, 10350 mg, 10400 mg, 10450 mg, 10500 mg, 10550 mg, 10600 mg, 10650 mg, 10700 mg, 10750 mg, 10800 mg, 10850 mg, 10900 mg, 10950 mg, 11000 mg, 11050 mg, 11100 mg, 11150 mg, 11200 mg, 11250 mg, 11300 mg, 11350 mg, 11400 mg, 11450 mg, 11500 mg, 11550 mg, 11600 mg, 11650 mg, 11700 mg, 11750 mg, 11800 mg, 11850 mg, 11900 mg, 11950 mg, 12000 mg, 12050 mg, 12100 mg, 12150 mg, 12200 mg, 12250 mg, 12300 mg, 12350 mg, 12400 mg, 12450 mg, 12500 mg, 12550 mg, 12600 mg, 12650 mg, 12700 mg, 12750 mg, 12800 mg, 12850 mg, 12900 mg, 12950 mg, 13000 mg, 13050 mg, 13100 mg, 13150 mg, 13200 mg, 13250 mg, 13300 mg, 13350 mg, 13400 mg, 13450 mg, 13500 mg, 13550 mg, 13600 mg, 13650 mg, 13700 mg, 13750 mg, 13800 mg, 13850 mg, 13900 mg, 13950 mg, 14000 mg, 14050 mg, 14100 mg, 14150 mg, 14200 mg, 14250 mg, 14300 mg, 14350 mg, 14400 mg, 14450 mg, 14500 mg, 14550 mg, 14600 mg, 14650 mg, 14700 mg, 14750 mg, 14800 mg, 14850 mg, 14900 mg, 14950 mg, 15000 mg, 15050 mg, 15100 mg, 15150 mg, 15200 mg, 15250 mg, 15300 mg, 15350 mg, 15400 mg, 15450 mg, 15500 mg, 15550 mg, 15600 mg, 15650 mg, 15700 mg, 15750 mg, 15800 mg, 15850 mg, 15900 mg, 15950 mg, 16000 mg, 16050 mg, 16100 mg, 16150 mg, 16200 mg, 16250 mg, 16300 mg, 16350 mg, 16400 mg, 16450 mg, 16500 mg, 16550 mg, 16600 mg, 16650 mg, 16700 mg, 16750 mg, 16800 mg, 16850 mg, 16900 mg, 16950 mg, 17000 mg, 17050 mg, 17100 mg, 17150 mg, 17200 mg, 17250 mg, 17300 mg, 17350 mg, 17400 mg, 17450 mg, 17500 mg, 17550 mg, 17600 mg, 17650 mg, 17700 mg, 17750 mg, 17800 mg, 17850 mg, 17900 mg, 17950 mg, 18000 mg, 18050 mg, 18100 mg, 18150 mg, 18200 mg, 18250 mg, 18300 mg, 18350 mg, 18400 mg, 18450 mg, 18500 mg, 18550 mg, 18600 mg, 18650 mg, 18700 mg, 18750 mg, 18800 mg, 18850 mg, 18900 mg, 18950 mg, 19000 mg, 19050 mg, 19100 mg, 19150 mg, 19200 mg, 19250 mg, 19300 mg, 19350 mg, 19400 mg, 19450 mg, 19500 mg, 19550 mg, 19600 mg, 19650 mg, 19700 mg, 19750 mg, 19800 mg, 19850 mg, 19900 mg, 19950 mg, 20000 mg, 20050 mg, 20100 mg, 20150 mg, 20200 mg, 20250 mg, 20300 mg, 20350 mg, 20400 mg, 20450 mg, 20500 mg, 20550 mg, 20600 mg, 20650 mg, 20700 mg, 20750 mg, 20800 mg, 20850 mg, 20900 mg, 20950 mg, 21000 mg, 21050 mg, 21100 mg, 21150 mg, 21200 mg, 21250 mg, 21300 mg, 21350 mg, 21400 mg, 21450 mg, 21500 mg, 21550 mg, 21600 mg, 21650 mg, 21700 mg, 21750 mg, 21800 mg, 21850 mg, 21900 mg, 21950 mg, 22000 mg, 22050 mg, 22100 mg, 22150 mg, 22200 mg, 22250 mg, 22300 mg, 22350 mg, 22400 mg, 22450 mg, 22500 mg, 22550 mg, 22600 mg, 22650 mg, 22700 mg, 22750 mg, 22800 mg, 22850 mg, 22900 mg, 22950 mg, 23000 mg, 23050 mg, 23100 mg, 23150 mg, 23200 mg, 23250 mg, 23300 mg, 23350 mg, 23400 mg, 23450 mg, 23500 mg, 23550 mg, 23600 mg, 23650 mg, 23700 mg, 23750 mg, 23800 mg, 23850 mg, 23900 mg, 23950 mg, 24000 mg, 24050 mg, 24100 mg, 24150 mg, 24200 mg, 24250 mg, 24300 mg, 24350 mg, 24400 mg, 24450 mg, 24500 mg, 24550 mg, 24600 mg, 24650 mg, 24700 mg, 24750 mg, 24800 mg, 24850 mg, 24900 mg, 24950 mg, 25000 mg, 25050 mg, 25100 mg, 25150 mg, 25200 mg, 25250 mg, 25300 mg, 25350 mg, 25400 mg, 25450 mg, 25500 mg, 25550 mg, 25600 mg, 25650 mg, 25700 mg, 25750 mg, 25800 mg, 25850 mg, 25900 mg, 25950 mg, 26000 mg, 26050 mg, 26100 mg, 26150 mg, 26200 mg, 26250 mg, 26300 mg, 26350 mg, 26400 mg, 26450 mg, 26500 mg, 26550 mg, 26600 mg, 26650 mg, 26700 mg, 26750 mg, 26800 mg, 26850 mg, 26900 mg, 26950 mg, 27000 mg, 27050 mg, 27100 mg, 27150 mg, 27200 mg, 27250 mg, 27300 mg, 27350 mg, 27400 mg, 27450 mg, 27500 mg, 27550 mg, 27600 mg, 27650 mg, 27700 mg, 27750 mg, 27800 mg, 27850 mg, 27900 mg, 27950 mg, 28000 mg, 28050 mg, 28100 mg, 28150 mg, 28200 mg, 28250 mg, 28300 mg, 28350 mg, 28400 mg, 28450 mg, 28500 mg, 28550 mg, 28600 mg, 28650 mg, 28700 mg, 28750 mg, 28800 mg, 28850 mg, 28900 mg, 28950 mg, 29000 mg, 29050 mg, 29100 mg, 29150 mg, 29200 mg, 29250 mg, 29300 mg, 29350 mg, 29400 mg, 29450 mg, 29500 mg, 29550 mg, 29600 mg, 29650 mg, 29700 mg, 29750 mg, 29800 mg, 29850 mg, 29900 mg, 29950 mg, 30000 mg, 30050 mg, 30100 mg, 30150 mg, 30200 mg, 30250 mg, 30300 mg, 30350 mg, 30400 mg, 30450 mg, 30500 mg, 30550 mg, 30600 mg, 30650 mg, 30700 mg, 30750 mg, 30800 mg, 30850 mg, 30900 mg, 30950 mg, 31000 mg, 31050 mg, 31100 mg, 31150 mg, 31200 mg, 31250 mg, 31300 mg, 31350 mg, 31400 mg, 31450 mg, 31500 mg, 31550 mg, 31600 mg, 31650 mg, 31700 mg, 31750 mg, 31800 mg, 31850 mg, 31900 mg, 31950 mg, 32000 mg, 32050 mg, 32100 mg, 32150 mg, 32200 mg, 32250 mg, 32300 mg, 32350 mg, 32400 mg, 32450 mg, 32500 mg, 32550 mg, 32600 mg, 32650 mg, 32700 mg, 32750 mg, 32800 mg, 32850 mg, 32900 mg, 32950 mg, 33000 mg, 33050 mg, 33100 mg, 33150 mg, 33200 mg, 33250 mg, 33300 mg, 33350 mg, 33400 mg, 33450 mg, 33500 mg, 33550 mg, 33600 mg, 33650 mg, 33700 mg, 33750 mg, 33800 mg, 33850 mg, 33900 mg, 33950 mg, 34000 mg, 34050 mg, 34100 mg, 34150 mg, 34200 mg, 34250 mg, 34300 mg, 34350 mg, 34400 mg, 34450 mg, 34500 mg, 34550 mg, 34600 mg, 34650 mg, 34700 mg, 34750 mg, 34800 mg, 34850 mg, 34900 mg, 34950 mg, 35000 mg, 35050 mg, 35100 mg, 35150 mg, 35200 mg, 35250 mg, 35300 mg, 35350 mg, 35400 mg, 35450 mg, 35500 mg, 35550 mg, 35600 mg, 35650 mg, 35700 mg, 35750 mg, 35800 mg, 35850 mg, 35900 mg, 35950 mg, 36000 mg, 36050 mg, 36100 mg, 36150 mg, 36200 mg, 36250 mg, 36300 mg, 36350 mg, 36400 mg, 36450 mg, 36500 mg, 36550 mg, 36600 mg, 36650 mg, 36700 mg, 36750 mg, 36800 mg, 36850 mg, 36900 mg, 36950 mg, 37000 mg, 37050 mg, 37100 mg, 37150 mg, 37200 mg, 37250 mg, 37300 mg, 37350 mg, 37400 mg, 37450 mg, 37500 mg, 37550 mg, 37600 mg, 37650 mg, 37700 mg, 37750 mg, 37800 mg, 37850 mg, 37900 mg, 37950 mg, 38000 mg, 38050 mg, 38100 mg, 38150 mg, 38200 mg, 38250 mg, 38300 mg, 38350 mg, 38400 mg, 38450 mg, 38500 mg, 38550 mg, 38600 mg, 38650 mg, 38700 mg, 38750 mg, 38800 mg, 38850 mg, 38900 mg, 38950 mg, 39000 mg, 39050 mg, 39100 mg, 39150 mg, 39200 mg, 39250 mg, 39300 mg, 39350 mg, 39400 mg, 39450 mg, 39500 mg, 39550 mg, 39600 mg, 39650 mg, 39700 mg, 39750 mg, 39800 mg, 39850 mg, 39900 mg, 39950 mg, 40000 mg, 40050 mg, 40100 mg, 40150 mg, 40200 mg, 40250 mg, 40300 mg, 40350 mg, 40400 mg, 40450 mg, 40500 mg, 40550 mg, 40600 mg, 40650 mg, 40700 mg, 40750 mg, 40800 mg, 40850 mg, 40900 mg, 40950 mg, 41000 mg, 41050 mg, 41100 mg, 41150 mg, 41200 mg, 41250 mg, 41300 mg, 41350 mg, 41400 mg, 41450 mg, 41500 mg, 41550 mg, 41600 mg, 41650 mg, 41700 mg, 41750 mg, 41800 mg, 41850 mg, 41900 mg, 41950 mg, 42000 mg, 42050 mg, 42100 mg, 42150 mg, 42200 mg, 42250 mg, 42300 mg, 42350 mg, 42400 mg, 42450 mg, 42500 mg, 42550 mg, 42600 mg, 42650 mg, 42700 mg, 42750 mg, 42800 mg, 42850 mg, 42900 mg, 42950 mg, 43000 mg, 43050 mg, 43100 mg, 43150 mg, 43200 mg, 43250 mg, 43300 mg, 43350 mg, 43400 mg, 43450 mg, 43500 mg, 43550 mg, 43600 mg, 43650 mg, 43700 mg, 43750 mg, 43800 mg, 43850 mg, 43900 mg, 43950 mg, 44000 mg, 44050 mg, 44100 mg, 44150 mg, 44200 mg, 44250 mg, 44300 mg, 44350 mg, 44400 mg, 44450 mg, 44500 mg, 44550 mg, 44600 mg, 44650 mg, 44700 mg, 44750 mg, 44800 mg, 44850 mg, 44900 mg, 44950 mg, 45000 mg, 45050 mg, 45100 mg, 45150 mg, 45200 mg, 45250 mg, 45300 mg, 45350 mg, 45400 mg, 45450 mg, 45500 mg, 45550 mg, 45600 mg, 45650 mg, 45700 mg, 45750 mg, 45800 mg, 45850 mg, 45900 mg, 45950 mg, 46000 mg, 46050 mg, 46100 mg, 46150 mg, 46200 mg, 46250 mg, 46300 mg, 46350 mg, 46400 mg, 46450 mg, 46500 mg, 46550 mg, 46600 mg, 46650 mg, 46700 mg, 46750 mg, 46800 mg, 46850 mg, 46900 mg, 46950 mg, 47000 mg, 47050 mg, 47100 mg, 47150 mg, 47200 mg, 47250 mg, 47300 mg, 47350 mg, 47400 mg, 47450 mg, 47500 mg, 47550 mg, 47600 mg, 47650 mg, 47700 mg, 47750 mg, 47800 mg, 47850 mg, 47900 mg, 47950 mg, 48000 mg, 48050 mg, 48100 mg, 48150 mg, 48200 mg, 48250 mg, 48300 mg, 48350 mg, 48400 mg, 48450 mg, 48500 mg, 48550 mg, 48600 mg, 48650 mg, 48700 mg, 48750 mg, 48800 mg, 48850 mg, 48900 mg, 48950 mg, 49000 mg, 49050 mg, 49100 mg, 49150 mg, 49200 mg, 49250 mg, 49300 mg, 49350 mg, 49400 mg, 49450 mg, 49500 mg, 49550 mg, 49600 mg, 49650 mg, 49700 mg, 49750 mg, 49800 mg, 49850 mg, 49900 mg, 49950 mg, 50000 mg, 50050 mg, 50100 mg, 50150 mg, 50200 mg, 50250 mg, 50300 mg, 50350 mg, 50400 mg, 50450 mg, 50500 mg, 50550 mg, 50600 mg, 50650 mg, 50700 mg, 50750 mg, 50800 mg, 50850 mg, 50900 mg, 50950 mg, 51000 mg, 51050 mg, 51100 mg, 51150 mg, 51200 mg, 51250 mg, 51300 mg, 51350 mg, 51400 mg, 51450 mg, 51500 mg, 51550 mg, 51600 mg, 51650 mg, 51700 mg, 51750 mg, 51800 mg, 51850 mg, 51900 mg, 51950 mg, 52000 mg, 52050 mg, 52100 mg, 52150 mg, 52200 mg, 52250 mg, 52300 mg, 52350 mg, 52400 mg, 52450 mg, 52500 mg, 52550 mg, 52600 mg, 52650 mg, 52700 mg, 52750 mg, 52800 mg, 52850 mg, 52900 mg, 52950 mg, 53000 mg, 53050 mg, 53100 mg, 53150 mg, 53200 mg, 53250 mg, 53300 mg, 53350 mg, 53400 mg, 53450 mg, 53500 mg, 53550 mg, 53600 mg, 53650 mg, 53700 mg, 53750 mg, 53800 mg, 53850 mg, 53900 mg, 53950 mg, 54000 mg, 54050 mg, 54100 mg, 54150 mg, 54200 mg, 54250 mg, 54300 mg, 54350 mg, 54400 mg, 54450 mg, 54500 mg, 54550 mg, 54600 mg, 54650 mg, 54700 mg, 54750 mg, 54800 mg, 54850 mg, 54900 mg, 54950 mg, 55000 mg, 55050 mg, 55100 mg, 55150 mg, 55200 mg, 55250 mg, 55300 mg, 55350 mg, 55400 mg, 55450 mg, 55500 mg, 55550 mg, 55600 mg, 55650 mg, 55700 mg, 55750 mg, 55800 mg, 55850 mg, 55900 mg, 55950 mg, 56000 mg, 56050 mg, 56100 mg, 56150 mg, 56200 mg, 56250 mg, 56300 mg, 56350 mg, 56400 mg, 56450 mg, 56500 mg, 56550 mg, 56600 mg, 56650 mg, 56700 mg, 56750 mg, 56800 mg, 56850 mg, 56900 mg, 56950 mg, 57000 mg, 57050 mg, 57100 mg, 57150 mg, 57200 mg, 57250 mg, 57300 mg, 57350 mg, 57400 mg, 57450 mg, 57500 mg, 57550 mg, 57600 mg, 57650 mg, 57700 mg, 57750 mg, 57800 mg, 57850 mg, 57900 mg, 57950 mg, 58000 mg, 58050 mg, 58100 mg, 58150 mg, 58200 mg, 58250 mg, 58300 mg, 58350 mg, 58400 mg, 58450 mg, 58500 mg, 58550 mg, 58600 mg, 58650 mg, 58700 mg, 58750 mg, 58800 mg, 58850 mg, 58900 mg, 58950 mg, 59000 mg, 59050 mg, 59100 mg, 59150 mg, 59200 mg, 59250 mg, 59300 mg, 59350 mg, 59400 mg, 59450 mg, 59500 mg, 59550 mg, 59600 mg, 59650 mg, 59700 mg, 59750 mg, 59800 mg, 59850 mg, 59900 mg, 59950 mg, 60000 mg, 60050 mg, 60100 mg, 60150 mg, 60200 mg, 60250 mg, 60300 mg, 60350 mg, 60400 mg, 60450 mg, 60500 mg, 60550 mg, 60600 mg, 60650 mg, 60700 mg, 60750 mg, 60800 mg, 60850 mg, 60900 mg, 60950 mg, 61000 mg, 61050 mg, 61100 mg, 61150 mg, 61200 mg, 61250 mg, 61300 mg, 61350 mg, 61400 mg, 61450 mg, 61500 mg, 61550 mg, 61600 mg, 61650 mg, 61700 mg, 61750 mg, 61800 mg, 61850 mg, 61900 mg, 61950 mg, 62000 mg, 62050 mg, 62100 mg, 62150 mg, 62200 mg, 62250 mg, 62300 mg, 62350 mg, 62400 mg, 62450 mg, 62500 mg, 62550 mg, 62600 mg, 62650 mg, 62700 mg, 62750 mg, 62800 mg, 62850 mg, 62900 mg, 62950 mg, 63000 mg, 63050 mg, 63100 mg, 63150 mg, 63200 mg, 63250 mg, 63300 mg, 63350 mg, 63400 mg, 63450 mg, 63500 mg, 63550 mg, 63600 mg, 63650 mg, 63700 mg, 63750 mg, 63800 mg, 63850 mg, 63900 mg, 63950 mg, 64000 mg, 64050 mg, 64100 mg, 64150 mg, 64200 mg, 64250 mg, 64300 mg, 64350 mg, 64400 mg, 64450 mg, 64500 mg, 64550 mg, 64600 mg, 64650 mg, 64700 mg, 64750 mg, 64800 mg, 64850 mg, 64900 mg, 64950 mg, 65000 mg, 65050 mg, 65100 mg, 65150 mg, 65200 mg, 65250 mg, 65300 mg, 65350 mg, 65400 mg, 65450 mg, 65500 mg, 65550 mg, 65600 mg, 65650 mg, 65700 mg, 65750 mg, 65800 mg, 65850 mg, 65900 mg, 65950 mg, 66000 mg, 66050 mg, 66100 mg, 66150 mg, 66200 mg, 66250 mg, 66300 mg, 66350 mg, 66400 mg, 66450 mg, 66500 mg, 66550 mg, 66600 mg, 66650 mg, 66700 mg, 66750 mg, 66800 mg, 66850 mg, 66900 mg, 66950 mg, 67000 mg, 67050 mg, 67100 mg, 67150 mg, 67200 mg, 67250 mg, 67

If immunosuppression is being tapered, then biopsies are obtained as often as every 3 months.

Outpatient biopsies are performed by transplant cardiologists in the Cardiac Catheterization Laboratory. The right ventricular endocardium is usually approached from the right internal jugular or subclavian vein, and approximately 6 specimens with a biptome are obtained for histopathologic study. Obtaining a minimum of 4 biopsy samples reduces the chance of missing rejection to 2%. Little information is added by obtaining more than 8 specimens, and the incidence of biopsies of previous sites increases with more than 8 samples per session. The procedure is performed in the morning, with results available within 24 hours. Typically the procedure requires 15 minutes or less. If necessary, the femoral approach can be used, but the risk of infection may be higher.

Endomyocardial biopsy is an uncomfortable but not a painful procedure. Once the importance of the procedure is realized by the patient, his or her cooperation is usually not difficult to obtain, and patients become less apprehensive with time.

MANAGEMENT

Immunosuppression. Prevention of rejection following orthotopic cardiac transplantation is critical. In contrast to kidney transplantation, rejection of the transplanted heart results in death since there are no reliable long-term support systems analogous to renal dialysis for the rejected kidney.

Cyclosporin A has been a major advance in the prevention of allograft rejection. Although the drug does not significantly reduce the number of rejection episodes, it reduces their severity and associated morbidity. It has been proposed that cyclosporin mediates its effects through inhibition of helper T cells, by inhibiting the generation of interleukin 2 and other lymphokines, thereby reducing proliferation of cytotoxic T lymphocytes.⁷

The mainstay of immunosuppression is a triple drug regimen consisting of cyclosporin, azathioprine, and prednisone. Cyclosporin is begun on postoperative day 2 (to allow time for recovery of renal function following transplantation). It is started at a dose of 2 to 4 mg/kg/day in two divided doses, and increased over several days to 8 to 10 mg/kg/day. It is later tapered to approximately 4 mg/kg/day by the end of the first year. In the immediate postoperative period,

TABLE 2 ANTIBIOTIC PROPHYLAXIS REGIMEN FOR OPPORTUNISTIC INFECTIONS	
Antibiotic	Duration
EVERY PATIENT	
Acyclovir 200 mg bid	2 months
Trimethoprim-sulfamethoxazole DS qd	2 months
Nystatin 200,000 units bid	3 months
TOXOPLASMA SEROLOGIC MISMATCH	
Replace trimethoprim-sulfamethoxazole with Pyrimethamine 50 mg qd	2 months
CMV SEROLOGIC MISMATCH	
Cytogam 150 mg/kg	Within 72 hours
100 mg/kg	at 2, 4, 6 and 8 wks
50 mg/kg	at 12 and 16 wks

polyclonal or monoclonal antilymphocyte globulin is given for 4 to 5 days for protection until cyclosporin levels rise. Blood levels are monitored and provide some guidance to dosage adjustments due to alterations in excretion.

Azathioprine is initiated preoperatively and continued postoperatively at 2 to 4 mg/kg/day, tapering over several weeks. The dosage is adjusted to maintain a WBC count of 4 to 6 $\times 10^3$ cells/ μ L. Prednisone is begun postoperatively at 1 mg/kg/day, and tapered over 4 weeks to 0.2 mg/kg/day. Further tapering after the first year is attempted if the rejection history permits.

Antimicrobial Prophylaxis. The transplant recipient is subject to a number of opportunistic infections (vide infra). A prophylactic regimen is initiated in all patients, designed to reduce the incidence of infection with cytomegalovirus, *Pneumocystis carinii*, *Candida* sp, herpes virus, and *Toxoplasma gondii*. This regimen is summarized in Table 2.

Drug Interactions. A number of commonly used drugs can affect metabolism and clearance of the immunosuppressant drugs. Cyclosporin is metabolized by the cytochrome P450 system in the liver, and one of its major side effects is nephrotoxicity. The suppression of the bone marrow by azathioprine can be altered by certain concomitant medications. Some of the better known interactions are given in Table 3.

TABLE 3
COMMONLY USED DRUGS WHICH INTERACT WITH
IMMUNOSUPPRESSANT DRUGS

Drug	Effect
AZATHIOPRINE	
Allopurinol	Increases effect of azathioprine
CYCLOSPORIN A	
Substantiated:	
Erythromycin	Increases cyclosporin levels
Ketoconazole	Increases cyclosporin levels
Rifampin	Decreases cyclosporin levels
Phenytoin	Decreases cyclosporin levels
Barbiturates	Decreases cyclosporin levels
Unsubstantiated:	
Aminoglycosides	Increased nephrotoxicity
Amphotericin B	Increased nephrotoxicity
Trimethoprim	Increased nephrotoxicity
Sulfamethoxazole	Increased nephrotoxicity
Cimetidine	Increased Nephrotoxicity
Corticosteroids	Increased cyclosporin levels
Diltiazem	Increased cyclosporin levels
INH	Decreased cyclosporin levels

COMPLICATIONS

Allograft Rejection. Rejection of the transplanted heart is not an uncommon event, but fortunately most of these rejections are mild using the current immunosuppression regimen. The symptoms of rejection are largely nonspecific. The patient may complain of fatigue and malaise. A low grade fever may develop. Physical examination may reveal a fourth heart sound, and the electrocardiogram may demonstrate atrial arrhythmias. A 20% decrease in the summation of the ECG voltages in leads I-III, V1 and V6 may be helpful in diagnosis, but is usually not present when cyclosporin is used for immunosuppression. Since physical findings, electrocardiography, and echocardiography are relatively insensitive, biopsy is performed for confirmation.

Rejection is classified as minimal, mild, moderate, or severe. Minimal rejection features only a few interstitial mononuclear cells. In mild rejection, there is interstitial or perivascular infiltration of mononuclear cells, but no damage to myocytes is detected. Moderate

rejection involves limited myocyte damage, and severe rejection involves hemorrhages and extensive neutrophil infiltration and myocyte damage.

During the first 3 months early (mild) rejection is treated with pulse methylprednisone (1 gram IV daily for 3 days). Most episodes respond to this therapy. If the follow-up biopsy does not show improvement, the oral prednisone dose is increased to 1 mg/kg/day then tapered over 2 weeks. After the first 3 months, mild rejection episodes are not treated, but closely monitored. Moderate and severe rejection require more extensive modification of the immunosuppression regimen.

Hypertension. Development of hypertension, primarily diastolic hypertension, is not uncommon following cardiac transplantation. The cause is unclear, but proposed theories include loss of neural control of blood pressure from cyclosporin, sodium and water retention, or enhanced activity of the renin-angiotensin system. Treatment with diuretics and calcium channel blockers is usually sufficient, but angiotensin converting enzyme (ACE) inhibitors or beta blockers may be required. If beta blockers are used, treadmill testing is performed to evaluate tolerance of the drug.

Renal Insufficiency. Another problem which occurs commonly following cardiac transplantation is mild to moderate renal insufficiency. Cyclosporin can impair renal function, perhaps by causing an arteriopathy of the renal arteriole secondary to decreased synthesis of prostacyclin stimulating factor.⁸ This would result in renal vasospasm, and may be a major contributor to renal dysfunction in those patients receiving the drug.

Acquired Infections. Infection is a major contributor to mortality and morbidity following cardiac transplantation. Early recognition and management of opportunistic infections is essential, since delay in treatment may result in a fulminant and fatal course. The intracellular microorganisms are of major concern in the immunosuppressed patient.

Current immunosuppression regimens result in depression in polymorphonuclear leukocyte (PMN) function, PMN counts, B-cell function and antibody production, and T-lymphocyte counts and function. The risk of infection with encapsulated bacteria, certain viruses, *Legionella*, mycobacteria, *Listeria*, fungi, and protozoans is increased (Table 4). Infections may result from endogenous organisms, or from organisms acquired from the environment. Another route is reactivation of latent infections, in particular with CMV, ►

TABLE 4
OPPORTUNISTIC INFECTIONS FOLLOWING
CARDIAC TRANSPLANTATION

	Organism	Common sites
BACTERIA	<i>Pneumococcus</i>	Lung
	<i>Hemophilus influenza</i>	Lung
	<i>Staphylococcus sp</i>	Lung, soft tissue
	<i>Escherichia coli</i>	Lung
	<i>Klebsiella sp</i>	Lung
	<i>Pseudomonas aeruginosa</i>	Lung
	<i>Legionella pneumophila</i>	Lung
	<i>Listeria monocytogenes</i>	CNS, blood
	<i>Nocardia sp</i>	Lung, CNS
FUNGI	<i>Mycobacteria sp</i>	Lung
	<i>Candida</i>	Oral, esophageal, systemic
	<i>Cryptococcus</i>	CNS, lung
	<i>Aspergillus</i>	Lung, CNS
	<i>Coccidioides</i>	Lung, CNS
PROTOZOA	<i>Toxoplasma gondii</i>	CNS, liver, heart, eye
	<i>Pneumocystis carinii</i>	Lung
VIRUSES	CMV	Lung, liver, retina, systemic
	<i>Herpes simplex</i>	Oral, esophageal, CNS
	Epstein-Barr	Lymphoid tissue
	Varicella-Zoster	Skin, systemic

Epstein-Barr virus, varicella-zoster, tuberculosis, and toxoplasma. A final route, discussed in the next section, is transmission from an infected donor organ to a noninfected recipient.

The most common site of opportunistic infection is the lungs. A less common site, but one associated with greater morbidity, is the CNS. An important feature of infections in the post cardiac transplant patient is that the reduction in PMN counts, PMN function, and macrophage-monocyte function may mask early clinical signs of infection. A high index of suspicion and vigilance must therefore be maintained in the post-transplantation period, and aggressive evaluation and treatment of infectious complications is necessary.

Donor-Transmitted Infections. The transmission of

infection through a donor heart to an uninfected recipient can have significant morbidity and mortality. The organisms which can be involved include *Cytomegalovirus* (CMV), *Toxoplasma gondii*, Hepatitis B virus (HBV), and human immunodeficiency virus (HIV).

The most significant route of CMV infection in heart transplant recipients is through the transplanted heart. Donor acquired CMV infection is much more serious than primary CMV acquired from other routes, such as blood transfusion. At present the best means of reducing the impact of CMV infection is to obtain a serologic match between donor and recipient (seropositive donor hearts are transplanted into seropositive recipients, and seronegative hearts into seronegative recipients). The most severe infections occur following transplantation of a seropositive donor into a seronegative recipient. Rapid screening tests now make pre-transplantation determination of seropositivity possible.

Most primary infections with *T gondii* in heart transplant recipients are acquired from the organs of donors seropositive for the organism by a recipient who is seronegative. Although pretransplantation serologic screening is not available as it is for CMV, determination of serologic status is obtained at the time of transplantation. Serologic mismatched patients can undergo prophylaxis in the post-transplantation period, and the incidence of *T gondii* infections can therefore be nearly eliminated.

Other infections which can be transmitted via donor organ to the recipient are HIV and Hepatitis B virus. Pretransplantation screening can identify HIV and HBV infection in potential donors, and therefore use of organs from infected donors can be avoided.

Hyperlipidemia. All patients are started on a low cholesterol-low saturated fat diet. We have refrained from routine use of Lovastatin or similar drugs because of a high incidence of rhabdomyolysis when used in conjunction with cyclosporin. All patients with low HDL are encouraged to start exercise programs and work toward weight reduction if indicated. The drug of choice for initial treatment is Lopid 600 mg twice daily. If there is no response to diet and Lopid, Mevacor 20 mg/day is considered. Very close follow-up and monitoring is necessary in either drug regimen.


Interaction of lipids and cyclosporin have important clinical implications. Cyclosporin affects lipoprotein metabolism by raising LDL cholesterol and triglycerides.

Accelerated Coronary Atherosclerosis. The two most important complications limiting survival after transplantation are acute allograft rejection and opportunistic infection. Another important complication which affects allograft recipients later in the postoperative course is the development of occlusive disease of the epicardial coronary arteries. The relatively high incidence of accelerated graft atherosclerosis (AGAS) in post-transplant patients is well known, but the exact pathophysiology is poorly understood. Theories include preoperative or intraoperative immune endothelial damage, abnormal lipid metabolism, perhaps combined with platelet activation. Histologically, the process is characterized by diffuse concentric lesions, causing narrowing of the intimal lumen, and lack of collateral vessels. This remains a major cause of late graft failure in heart transplant recipients. It is estimated that up to 50% of patients develop this type of coronary artery lesion within 5 years after transplantation. Some patients develop coronary artery disease after the first 5 years, and this group generally has less rapid progression.

Prevention is attempted by lowering risk factors, including a low cholesterol and low fat diet, weight reduction if indicated, a regular exercise regimen, control of hypertension, and cessation of cigarette smoking and alcohol consumption. Antiplatelet therapy is often advocated but does not appear to help. The use of cyclosporin does not appear to reduce the incidence of AGAS. One recent study suggests that the calcium channel blocker diltiazem may reduce the progression of the disease, but further study is required.⁹

There may be little warning of the presence of advanced lesions, and sudden death is frequently the presenting sign. The patient does not experience angina since the transplanted heart is denervated. There may be ischemic changes on the ECG, or the development of ventricular arrhythmias or congestive heart failure without evidence of acute allograft rejection.

Treadmill testing is insensitive in detecting the lesion, and coronary angiography is required for diagnosis. We routinely perform right and left heart catheterization on an annual basis. Because of cardiac denervation, heart transplant recipients do not develop angina and may develop silent myocardial infarctions or heart failure. Isolated single coronary artery lesions in the donor heart may be present at the time of transplantation. These isolated lesions can be treated with PTCA, aortocoronary bypass surgery, or retrans-



... a full service
Outpatient Diagnostic Clinic
Designed with your patient in mind.

OUTPATIENT DIAGNOSTIC CENTER OF NEW ORLEANS

• Routine X-Rays • CT Scan • Ultrasound • Nuclear Medicine •
MRI • Mammography • EKG • Lab

MAMMOGRAPHIC SCREENING \$60.00

Convenience

APPOINTMENTS — Not necessary for routine X-ray exams (i.e. chest, spine, extremities, mammo., etc.)
BILLING — We file INSURANCE forms or accept cash, check, MC/VISA.
Location — NAPOLEON MEDICAL PLAZA
FREE PARKING

CARE, COMFORT, CONVENIENCE
2320 Napoleon Ave. • Suite 300 • (504) 897-4455

plantation. Initial success and the restenosis rate in this group appears to be the same as nontransplant patients undergoing PTCA. Unfortunately, the lesion of accelerated graft atherosclerosis is a more diffuse lesion and not amenable to surgical intervention. In advanced stages, the only therapeutic option is retransplantation.

REFERENCES

1. Oyer PE, Stinson EB, Jamieson SW, et al. Cyclosporin-A in cardiac allografting: a preliminary experience. *Transplant Proc* 1983;15:1247-1252.
2. Valentine HA, Fowler MB, Hatle LK, et al. Doppler echocardiographic indices of diastolic function as markers of acute cardiac rejection. *Transplant Proc* 1987;19:2556-2559.
3. Desruennes M, Corcos T, Cabrol A, et al. Doppler echocardiography for the diagnosis of acute cardiac allograft rejection. *J Am Coll Cardiol* 1988;12:63-70.
4. Billingham ME. Endomyocardial biopsy detection of acute rejection in cardiac allograft recipients. *Heart Vess* 1986;1(Suppl 1):86-90.
5. Devineni R, Keown P, McKenzie N, et al. Cyclosporin in cardiac transplantation: observations on immunologic monitoring, cardiac histology, and cardiac function. *Heart Transplant* 1983;2:219-223.
6. Ueda K, Baumgartner WA, Beschoner WE, et al. Histologic pattern of early heart allograft rejection under cyclosporin treatment. *Heart Transplant* 1985;3:296-300.
7. Hess AD, Tutschka PJ. Effect of cyclosporin A on human lymphocyte responses in vivo. *J Immunol* 1980;124:2601-2608.
8. Kahan BD. Cyclosporin: the agent and its actions. *Transplant Proc* 1985;17(Suppl 1):5-18.
9. Schroeder JS, Gao S-Z, Alderman EL, et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. *N Engl J Med* 1993;328:164-170.

The authors are from the Willis Knighton-LSU Medical Center Heart and Lung Transplantation Center in Shreveport, LA.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☒ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.